Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells

BACKGROUND: Bladder cancer is a common urinary system tumor. In the treatment of clinical patients, it is particularly important to find an effective treatment method to inhibit tumor growth. The world's first PARP inhibitor olaparib is mainly used for the treatment of BRCA1/BRCA2 mutated tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Bao-Jin, Sun, Yao, Quan, Ling-Li, Zhao, Jin-Tao, Wei, Bo, Wang, Shu-Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249502/
https://www.ncbi.nlm.nih.gov/pubmed/35783012
http://dx.doi.org/10.1155/2022/5709259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249502/
https://www.ncbi.nlm.nih.gov/pubmed/35783012
http://dx.doi.org/10.1155/2022/5709259

Ejemplares similares